Ifo-Cell N 1000

Ifosfamide, the active ingredient in Ifo-Cell N 1000, is an alkylating agent presented as a sterile injectable solution for intravenous use. It interferes with DNA replication and is employed in the treatment of several solid tumours and hematologic malignancies in adult patients. GNH USA supplies Ifo-Cell N 1000 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ifosfamide is an alkylating chemotherapy used in the treatment of several solid tumours and hematologic malignancies. Testicular cancer: provides cytotoxic activity to eradicate malignant germ‑cell tumors. Soft tissue sarcoma: reduces tumor burden and improves surgical outcomes. Lymphoma: contributes to remission in aggressive non‑Hodgkin subtypes. Bladder cancer: used as part of combination regimens for invasive disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: often requires anti‑emetic prophylaxis. - Fatigue: generalized tiredness during treatment cycles. - Alopecia: reversible hair loss. - Myelosuppression: decreased blood cell counts. - Hemorrhagic cystitis: bladder irritation due to metabolites. - Electrolyte disturbances: especially hyponatremia.

Serious or Rare Side Effects: - Nephrotoxicity: impaired renal function requiring monitoring. - Neurotoxicity: encephalopathy or seizures in high doses. - Secondary malignancies: risk of therapy‑related cancers. - Severe infection: opportunistic infections due to immunosuppression. - Anaphylactic reactions: rare hypersensitivity to the formulation. - Cardiotoxicity: occasional cardiac dysfunction.

Safety considerations are essential when handling this cytotoxic agent. - Hydration: ensure adequate intravenous fluids to reduce renal toxicity. - Mesna co‑administration: protect the bladder from hemorrhagic cystitis. - Renal monitoring: assess serum creatinine and electrolytes before each cycle. - Hepatic function: evaluate liver enzymes as metabolism occurs hepatically. - Myelosuppression monitoring: perform regular complete blood counts. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Potential drug‑drug interactions may affect efficacy or increase toxicity.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): amplify renal damage. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise active metabolite levels. - Other alkylating agents: heighten myelosuppression risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): alter INR, requiring dose adjustment. - Concurrent myelosuppressive drugs: increase risk of severe cytopenias.